Issue 30

Dr. Carl Hart on the Impediment of Prolonged Research

Lengthy clinical trials and the siphoning of well-studied, ‘textbook’ psychedelics through a cumbersome medical approval regime are unnecessary in 2021, says Dr. Carl Hart.

PSYCH caught up with the American psychologist and neuroscientist last week following the release of his new book, Drug Use for Grown-Ups. Along with discussion on the book, Hart shared his opinion on the role of the medical industry in drug access and the necessity for public education.

Read More

MAGICMED INDUSTRIES TO BE ACQUIRED BY NASDAQ-LISTED ENVERIC BIOSCIENCES

All-stock deal and uplisting provide an attractive opportunity to raise capital, company officials say.

Read More

MINDMED PUBLISHES FIRST PHARMACOGENETIC DATA ON PERSONALISED LSD DOSING

The collaborative study with University Hospital Basel’s Liechti Lab may inform the approach to individual dosing of LSD.

Read More

BUSINESS AND INVESTMENT

Braxia Scientific launches training centre focused on advancing psychedelic treatment therapy.

Field Trip appoints former US Senate Majority Leader as Special Adviser.

Cybin launching psilocybin trial for patients with Major Depressive Disorder.

CURE Pharmaceutical Q1 revenue quadruples and company announces development of psychedelics.

Mydecine approved to expand psilocybin cultivation capabilities.

Silo Pharma submits application for NASDAQ up-listing.

PharmaTher files application for ketamine to treat Lou Gehrig’s disease.

Cybin files patent to bolster range of novel psychedelics and delivery mechanisms.

Wake Network completes first legal psilocybin import into the US.

Woven Science launches psychedelic care platform with oversubscribed US$8.5 million seed financing.

MindMed’s clinical trial to assess effects of mescaline approved by ethics committee.

Wesana Health appoints Chief Scientific Officer to lead on research and drug development.

Mimosa Therapeutics CEO discusses pioneering in the psilocybin space.

Clearmind Medicine completes Change of Business listing to underline psychoactive pharmaceuticals focus.

MindMed announces partnership with Nextage Therapeutics to optimise psychedelic drug delivery.

Tryp Therapeutics partners with Alcami for a programme treating neuropsychiatric disorders with psilocybin.

Register for the PSYCH Investor Summit: Research & Development

Are you keeping up to date on the latest advancements in psychedelic science? Then join us on 7 July for the PSYCH Investor Summit: Research & Development, the must-attend virtual global event for investors and funds eyeing the most promising opportunities in psychedelics today.

Learn how research is paving the way for industry growth; discover the likely timeline for drug trials and commercialisation; and meet one-on-one with the groups and researchers leading the charge.

SECURE YOUR SEAT

RESEARCH AND SCIENCE

Examining Imperial College’s psilocybin study in The Psychedelic Drug Trial.

Psychedelics may help relieve the symptoms of autism spectrum disorder.

Single dose of psilocybin may treat migraines.

Clinic in Tennessee starts using ketamine to treat mood disorders.

Vancouver company testing DMT as treatment option for strokes.

Understanding the differences between ketamine and other psychedelics key to treating mental health.

Scientists find evidence that psychedelic drugs can lower barriers that constrain thoughts.

MDMA may help to treat post-traumatic stress disorder.

REGULATION AND LEGISLATION

Bill to decriminalise certain psychedelics in California heads to full senate vote.

Doctors in Massachusetts support more psychedelics research.

Eight US states side with cancer patients in psilocybin lawsuit against DEA.

Texas Senate approves cannabis concentrates and psychedelics bills.

Partner with us